Phase 2Completed
Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
- Sponsor
- AstraZeneca (Industry)
- Enrollment
- 116 enrolled
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin; Placebo
- Ages
- adults, older adults
- Registry
- NCT00831779
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity
Primary outcomes
- Adjusted Mean Percent Change From Baseline in Insulin Sensitivity at Week 12 (Last Observation Carried Forward [LOCF])
History
Last registry update
Results first posted
Primary completion
Started
Registered